CRIS · Company research
Curis Inc (CRIS): Stock News & Events
Recent company-linked news records available in the database.
RESEARCH CONTEXT
Understand the numbers
Recent company-linked news records available in the database. Use period, currency, units and source fields when interpreting values.
15records availableHealthcare
Stock News & Events data
Database-backed records only
| title | summary | url | source | published at | sentiment | sentiment score | relevance score |
|---|---|---|---|---|---|---|---|
| Curis (CRIS) Announces $8.5M Stock and Warrant Offering to Insti - GuruFocus | Curis (CRIS) Announces $8.5M Stock and Warrant Offering to Insti GuruFocus | View source ↗ | GuruFocus | Oct 16, 2026 | neutral | 0 | 0.6 |
| Curis (CRIS) Prices $8.5M Private Placement to Fund R&D and Corp - GuruFocus | Curis (CRIS) Prices $8.5M Private Placement to Fund R&D and Corp GuruFocus | View source ↗ | GuruFocus | Oct 16, 2026 | neutral | 0 | 0.6 |
| Bucharest stocks start week in green, Cris-Tim paces blue-chip gainers - SeeNews | Bucharest stocks start week in green, Cris-Tim paces blue-chip gainers SeeNews | View source ↗ | SeeNews | Oct 5, 2026 | neutral | 0 | 0.6 |
| Bucharest stocks end week in green, Cris-Tim paces blue-chip gainers - SeeNews | Bucharest stocks end week in green, Cris-Tim paces blue-chip gainers SeeNews | View source ↗ | SeeNews | Oct 2, 2026 | neutral | 0 | 0.6 |
| CRIS Stock Price, Quote & Chart - ChartMill | CRIS Stock Price, Quote & Chart ChartMill | View source ↗ | ChartMill | Sep 25, 2026 | neutral | 0 | 0.6 |
| Curis (CRIS) Stock Fair Value Moves Lower After Emavusertib TakeAim Model Rework - Yahoo Finance | Curis (CRIS) Stock Fair Value Moves Lower After Emavusertib TakeAim Model Rework Yahoo Finance | View source ↗ | Yahoo Finance | Aug 5, 2026 | neutral | 0 | 0.6 |
| Curis (CRIS) FDA Approvals, PDUFA Dates & Drug Alerts 2026 $CRIS - MarketBeat | Curis (CRIS) FDA Approvals, PDUFA Dates & Drug Alerts 2026 $CRIS MarketBeat | View source ↗ | MarketBeat | Jul 22, 2026 | neutral | 0 | 0.6 |
| Curis reaches first 6 patients in CLL study, July dosing on track - Stock Titan | Curis reaches first 6 patients in CLL study, July dosing on track Stock Titan | View source ↗ | Stock Titan | Jul 6, 2026 | neutral | 0 | 0.6 |
| Why Did Curis (CRIS) Stock Soar After Hours? - Benzinga | Why Did Curis (CRIS) Stock Soar After Hours? Benzinga | View source ↗ | Benzinga | Jul 2, 2026 | neutral | 0 | 0.6 |
| Curis Announces Eleven Active Clinical Sites in TakeAim CLL Study, Reaffirms Patient Dosing Guidance, and Reports Stockholder Approval of Reverse Stock Split - PR Newswire | Curis Announces Eleven Active Clinical Sites in TakeAim CLL Study, Reaffirms Patient Dosing Guidance, and Reports Stockholder Approval of Reverse Stock Split PR Newswire | View source ↗ | PR Newswire | Jun 26, 2026 | neutral | 0 | 0.6 |
| CRIS: Reverse stock split and adjournment proposals were both approved by majority vote - TradingView | CRIS: Reverse stock split and adjournment proposals were both approved by majority vote TradingView | View source ↗ | TradingView | Jun 25, 2026 | neutral | 0 | 0.6 |
| Curis (CRIS) Stock Faces Mixed Analyst Target Changes Over Execution And Pipeline Risk - Yahoo Finance | Curis (CRIS) Stock Faces Mixed Analyst Target Changes Over Execution And Pipeline Risk Yahoo Finance | View source ↗ | Yahoo Finance | Jun 23, 2026 | neutral | 0 | 0.6 |
| $CRIS stock is up 23% today. Here's what we see in our data. - Quiver Quantitative | $CRIS stock is up 23% today. Here's what we see in our data. Quiver Quantitative | View source ↗ | Quiver Quantitative | Apr 15, 2026 | neutral | 0 | 0.6 |
| CRIS Should I Buy - Intellectia AI | CRIS Should I Buy Intellectia AI | View source ↗ | Intellectia AI | Apr 5, 2026 | neutral | 0 | 0.6 |
| Why Investors Shouldn't Be Surprised By Curis, Inc.'s (NASDAQ:CRIS) 27% Share Price Plunge - Simply Wall Street | Why Investors Shouldn't Be Surprised By Curis, Inc.'s (NASDAQ:CRIS) 27% Share Price Plunge Simply Wall Street | View source ↗ | Simply Wall Street | Jan 4, 2026 | neutral | 0 | 0.6 |
Informational research only, not financial advice. Forecasts are uncertain and can be wrong.